Results 321 to 330 of about 148,079 (360)

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

Protective effect of metformin on periapical lesions in rats by decreasing the ratio of receptor activator of nuclear factor kappa B ligand/osteoprotegerin.

Journal of Endodontics, 2012
Lingshuang Liu, Chi Zhang, Yajing Hu, B. Peng   +3 more
semanticscholar   +1 more source

Receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in sites of chronic periodontitis of subjects with poorly and well-controlled type 2 diabetes.

The Journal of Periodontology, 2010
V. R. Santos, J. A. Lima, T. D. Gonçalves, M. Bastos, L. Figueiredo, J. Shibli, P. Duarte   +6 more
semanticscholar   +1 more source

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Victoria Metaxa, Elie Azoulay   +2 more
exaly  

Possible mechanisms of the crosstalk between Langerhans cells and regulatory T cells in extramammary Paget disease by receptor activator of nuclear factor kappa B (RANK) ligand/RANK pathways

British Journal of Dermatology, 2017
T. Fujimura, Y. Kambayashi, S. Furudate, Aya Kakizaki, T. Hidaka, S. Aiba   +5 more
semanticscholar   +1 more source

Calcium/calmodulin‐dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL)

Journal of Cellular Physiology, 2007
E. Ang, Ping Zhang, J. Steer, J. W. Tan, Kirk Yip, M. Zheng, D. Joyce, Jiake Xu   +7 more
semanticscholar   +1 more source

Expression of receptor activator of nuclear factor kappa‐B as a poor prognostic marker in breast cancer

Journal of Surgical Oncology, 2014
Hyung seok Park, Ahwon Lee, B. Chae, J. Bae, B. Song, S. Jung   +5 more
semanticscholar   +1 more source

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly  

Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2.

Archives of Oral Biology, 2015
Takayuki Nakagawa, K. Ohta, Kazumi Kubozono, Y. Ishida, T. Naruse, M. Takechi, N. Kamata   +6 more
semanticscholar   +1 more source